Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Approval Alert | Ribociclib/NSAI in HR+/HER2- Stage II-III Early Breast Cancer
Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
